WG
NMRA icon

Winton Group’s Neumora Therapeutics NMRA Stock Holding History

Winton Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8K Buy
14,600
+4,500
+45% +$8.57K ﹤0.01% 1134
2026
Q1 		$19.7K Buy
+10,100
New +$26.2K ﹤0.01% 1079

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Winton Group's NMRA Position: Q2 2026 in Review

Winton Group increased its Neumora Therapeutics (NMRA) stake by 45% in Q2 2026, buying an estimated $8.57K and bringing the position to 14,600 shares worth $24.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1134.

Winton Group first reported a position in NMRA in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Winton Group held 14,600 shares of Neumora Therapeutics worth $24.8K as of Q2 2026.
  • Winton Group bought 4,500 Neumora Therapeutics shares in Q2 2026, an estimated $8.57K.
  • Neumora Therapeutics made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1134 holding.
  • Winton Group first reported a position in Neumora Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.